Lexaria Corp CSE:LXX OTC:LXRP

The LCBO said that the first Ontario Cannabis Store locations will be in Guelph, Kingston, Toronto and Thunder Bay. Just 4 locations, bet there will be massive line ups. I would think many will continue through current medical channels.

The lineups should make good headlines lol

TORONTO, April 9, 2018

HMMJ remains the world's largest Marijuana ETF

TORONTO, April 9, 2018 /CNW/ - Horizons ETFs Management (Canada) Inc. ("Horizons ETFs") is proud to announce that the Horizons Marijuana Life Sciences Index ETF ("HMMJ") has reached its one-year anniversary. HMMJ generated a one-year return for the period ending April 4, 2018, of 58.6% – making it the best-performing Canadian-listed ETF during this timeframe.

Since its inception on April 4, 2017, HMMJ – the world's first and largest Marijuana ETF – has brought in significant assets under management ("AUM"). Its AUM peaked at approximately $863 million on January 23, 2018 before market pull-backs. Its AUM now stands at over $622 million (as at April 6, 2018).

The Globe and Mail reports in its Monday edition that TD Bank is limiting the ways in which its advisers discuss the industry with clients, banning staff from recommending almost all marijuana firms and exchange-traded funds (ETFs). The Globe's Clare O'Hara and Christina Pellegrini write that TD is also prohibiting portfolio managers from pro-actively adding most cannabis shares to client investment accounts -- unless clients specifically instruct their adviser to do so. As a result, TD Wealth Private Investment Advice has put dozens of pot stocks and the four cannabis ETFs onto its non-approved list of securities, leaving advisers with only three Canadian marijuana stocks to suggest. As of Friday, TD advisers were approved to recommend the country's largest publicly traded producer of the drug, Canopy Growth, and two smaller, growers called Emerald Health Therapeutics and Emblem. The restrictions put on advisers who work at PIA appear to be driven out of concern of the legal risks the bank could face in the United States, where cannabis is legal in some states but illegal under federal law. The TD policy includes companies with no U.S. operations; it is not clear why those companies are included.

Great rebound in the stock. I added a bit on the dip as well

Yes, nice call. I bought some at $1.10

Looks like another nice call by Struthers to buy on weakness around $1.05. Thankyou Sir, nice bounce of that today

Stock came down to $1.05 area Ron highlighted. Added some stock there so hope we seen the bottom. Markets have seen quite a correction

Check out chart of the day, Ron has interesting sentiment chart compared to Canopy Growth WEED
www.playstocks.net/index.php/market-trends/chart-of-the-day

Lexaria Expands into Transdermal, Grows Licensing Revenue -- CFN Media

SEATTLE, April 04, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering Lexaria Bioscience Corp.’s (CSE:LXX) (LXX.CN) (CNSX:LXX) (OTCQB:LXRP) DehydraTECH™ which represents a breakthrough in cannabinoid drug delivery. Lexaria’s DehydraTECH™ is technology that promotes a molecular association between cannabinoids and certain fatty acid compounds that are known to have palatability and bio-absorption enhancing properties. This combination, in turn, results in improved cannabinoid taste, bioavailability and speed of effectiveness.

In the quickly expanding legal cannabis industry, effective delivery of the drug is an ongoing problem. Many consumers have taken to edible products as a healthier alternative to smoking, but there are still key issues with bioavailability and taste when infusing cannabinoids. Other delivery methods have gained in popularity as well, including topical creams and lotions. In addition to improving intestinal bio-absorption by as much as five to ten times in as little as 15 minutes, new laboratory study data has shown that the DehydraTECH™ technology is just as promising when it comes to transdermal applications.

Transdermal Applications

In March, the company announced the results from its first laboratory study of DehydraTECH™ on human skin at a California-based laboratory specializing in Franz diffusion cell skin permeability testing. Researchers compared the technology with two leading skin penetration enhancers, looking for penetration time, absorption quantity, and peak amounts of CBD absorbed into and through the skin at multiple testing intervals over 48 hours.

The researchers found that DehydraTECH™ was the fastest acting for absorption into the skin and demonstrated the highest overall average quantity of CBD delivered through the skin. In fact, the technology outperformed competing products by as much as 225%. The technology also lacked any odor, even without the use of perfumes, contrary to other cannabinoid industry products that can be quite odoriferous without the use of masking perfumes.

“We have theorized for some time that our DehydraTECH™ delivery system might have positive effects on skin-based delivery complementing its already commercialized gastro-intestinal product applications,” said Lexaria President John Docherty. “The first round of testing was very encouraging and showed clear benefits with regards to speed of action and, particularly, delivery of CBD across the skin barrier for potential transdermal applications.”

Building an IP Portfolio

Lexaria has already begun to commercialize the DehydraTECH™ delivery system, as well as build up its patent portfolio. Earlier this year, the company entered into two licensing agreements for the innovative platform with a cannabis edibles maker and a Canadian cannabis chocolate manufacturer. Under these agreements, the company has licensed out its technology for the development of edible products in exchange for licensing fees and royalties.

On March 22, the company announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office providing for a “composition of matter” claims that protect the specific combination of substances which enable improved taste and bio-absorption. This adds to the company’s existing “method of use” patent that had previously been granted, further protects its delivery system, and opens the door to further commercialization.

“This Notice of Allowance applies to the delivery of both psychoactive and non-psychoactive cannabinoids as lipophilic active agents formulated together with the edible fatty acids that enable the powerful bioavailability and taste enhancing properties of the DehydraTECH™ technology,” said Mr. Docherty. “This allowance has been granted by the USPTO upon review of the compelling scientific data Lexaria has amassed.”

Looking Ahead

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP) represents a compelling investment opportunity in the cannabis industry. By solving a key issue facing many edibles manufacturers, the company hopes to license its technology to a growing number of companies in exchange for licensing fees and royalties. These high-margin revenues could unlock significant value for shareholders over the long-term.

For more information, visit the company’s website or download their investor presentation.

Please follow the link to read the full article: www.cannabisfn.com/lexaria-expands-trans...s-licensing-revenue/

About CFN Media

CFN Media (CannabisFN) is the leading agency and financial media network dedicated to the global cannabis industry, helps companies operating in the space attract investors, capital, and publicity. Since 2013, private and public cannabis companies in the US and Canada have relied on CFN Media to grow and succeed.

Learn how to become a CFN Media client company, brand or entrepreneur: www.cannabisfn.com/featuredcompany

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: www.cannabisfn.com

Maybe a good buy, I think the sector will see another good rally ahead of summer legalization

Easter Bunny delivered an explosive egg. Markets getting hammered today and LXX among others going down with it

Another patent award coming, news out this morning

KELOWNA, BC / ACCESSWIRE / March 22, 2018 / Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces it has received a new Notice of Allowance from the United States Patent and Trademark Office ("USPTO") providing for "composition of matter" claims that protect the specific combination of substances which enable improved taste and bioabsorption properties of its DehydraTECH™ technology for the delivery of cannabinoids. This is a significant addition to Lexaria's existing manufacturing "method of use" patent rights previously granted.

"This Notice of Allowance applies to the delivery of both psychoactive and non-psychoactive cannabinoids as lipophilic active agents formulated together with the edible fatty acids that enable the powerful bioavailability and taste enhancing properties of the DehydraTECH™ technology," said John Docherty, President. "This allowance has been granted by the USPTO upon review of the compelling scientific data Lexaria has amassed demonstrating its significant bioavailability performance enhancement properties."

Under USPTO practice, there is no opposition period between allowance and issuance. The patent application number is 15/225,802, "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof." As has been Lexaria's experience in the past, the Company expects the formal granting of the new patent within roughly one hundred days or less.

Lexaria has additional patent applications that remain within the USPTO process, of both the composition of matter and process varieties. Lexaria will continue to develop and strengthen its patent portfolio in the USA, Canada, and internationally and expects further patent awards this year. As its patent portfolio increases, Lexaria will be better able to commercialize its technologies and defend its intellectual property.

Lexaria's patented DehydraTECH™ technology is focused on improved delivery methodologies of many commonly used active pharmaceutical ingredient ("API") substances. As such, it provides an additional layer of effectiveness that is designed to harmonize with the intellectual property of third parties. Both patented and generic API substances can utilize Lexaria's patented technology. Lexaria's long-term strategy is to partner with the world's leading firms as they deliver best-of-class products to their existing large consumer groups.